为了扩大现金储备，Cue Biopharma正在将重点从肿瘤候选产品转移到自身免疫性疾病产品线。

To extend its cash reserves, Cue Biopharma is shifting focus away from its oncology assets and will zero in on its autoimmune disease pipeline instead.

这家生物技术公司还将裁员25%。

The biotech is also slashing its workforce by 25%.

其临床前自身免疫管道的特点是和Ono制药公司合作的CUE-401，旨在增加调节性免疫T细胞的数量。

Its preclinical autoimmune pipeline features the Ono Pharmaceutical-partnered CUE-401, which is designed to increase the number of regulatory immune T cells.

还有CUE-501，可以引导选择性记忆T细胞消耗B细胞，以解决某些B细胞介导的自身免疫性疾病。

There is also CUE-501 that directs selective memory T cells to deplete B cells, which should address certain B cell-mediated autoimmune diseases.

该公司首席执行官丹·帕瑟里(Dan Passeri)表示，该公司仍在考虑这些产品用于哪些疾病的临床研究，预计今年下半年会有最新进展。

The company is still figuring out which diseases it would investigate these assets for in the clinic, with updates expected from the second half of this year, CEO Dan Passeri said in an email.

同时，根据周四发布的消息，Cue将保持“必要的临床能力”，为其正在寻找合作伙伴的1期肿瘤候选药物Cue -101和Cue -102完成研究，获得患者的生存数据。

Meanwhile, Cue will maintain the “requisite clinical capabilities” to generate mature survival data for its Phase 1 oncology candidates, CUE-101 and CUE-102, for which it is seeking partners, according to a Thursday release.

Stifel公司的分析师在一份报告中表示，优先考虑自身免疫项目的决定是“有意义的”。

Stifel analysts said in a note that the decision to prioritize autoimmune programs “made sense.”

他们写道，在某些头颈部鳞状细胞癌患者中，CUE-101和默克公司的Keytruda的剂量扩展数据有“差异”。

They wrote that the dose-expansion data for CUE-101 plus Merck’s Keytruda in certain patients with squamous cell carcinoma of the head and neck seemed “differentiated.”

然而，此次联合用药仅在一个小的适应症上进行了研究，因此难以吸引合作伙伴的“近期战略兴趣”。

However, the combination was only tested in a small indication, potentially making it difficult to attract “near-term strategic interest” from partners.

在员工方面，这家总部位于马萨诸塞州波士顿的公司将裁减研发和行政部门四分之一的员工。

As for its workforce, the Boston, MA-based company is axing a quarter of its staffers across R&D and administrative departments.

帕瑟里说，Cue大约有50名员工。

Cue had around 50 employees, Passeri said.

总的来说，产品线的再考虑和裁员能使公司的现金流延长到明年年中，并将其2025财年的运营费用削减25%至3000万美元。

Overall, the pipeline review and staff cuts should extend the company’s cash runway through the middle of next year and cut its fiscal year 2025 operating expenses by 25% to $30 million.

截至3月底，Cue公司拥有4,100万美元现金和现金等价物。

Cue ended March with $41 million in cash and cash equivalents.